Trial Profile
VISmodegib for ORbital and Periocular Basal Cell Carcinoma (VISORB)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Nov 2021
Price :
$35
*
At a glance
- Drugs Vismodegib (Primary)
- Indications Basal cell cancer; Orbital tumours
- Focus Therapeutic Use
- Acronyms VISORB
- 01 Jul 2021 Primary endpoint (The number of patients with a score of 21 or greater by the Visual Assessment Weighted Score (VAWS)) has been met, according to the results published in the Oncologist.
- 01 Jul 2021 Results published in the Oncologist
- 01 Jul 2021 Status changed from discontinued to completed.